Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next-generation sequencing of wild type and 5XFAD transcriptomes for Alzheimer's disease study

ABSTRACT: Next-generation sequencing of wild type and 5XFAD transcriptomes for Alzheimer's disease study

PROVIDER: PRJNA597779 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10769258_1.fastq.gz	Fastqsanger.gz
	SRR10769258_2.fastq.gz	Fastqsanger.gz
	SRR10769259_1.fastq.gz	Fastqsanger.gz
	SRR10769259_2.fastq.gz	Fastqsanger.gz
	SRR10769260_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 26

Similar Datasets

Next-generation sequencing of wild type and 5XFAD transcriptomes for Alzheimer's disease study

Project description:We found some novel miRNA that targets SIRT1 may contribute to the pathogenesis in AD mouse model. We first identified that SIRT1 is significantly reduced in Alzheimer patient`s precentral gyrus and 5XFAD mice. To determine whether the strategy of inhibiting some miRNA affects AD pathology, we synthesized antisense oligonucleotides of miRNA (miRNA ASO) and studied this sequence in the brain of 5XFAD through direct intracerebral ventricular injection using stereotaxic instrument. We identified miRNA ASO significantly reduced amyloid beta plaque and amyloid production enzyme. Importantly, the attenuation of amyloid beta plaques through miRNA ASO was caused by a phagocytic activity of glial cells, by which it can directly target CD36. miRNA ASO also decreases inflammatory responses. These results inhibit neuronal loss caused by amyloid beta and leading to improvement of cognitive impairment. These insights of miRNA ASO suggests as therapeutic scope against AD pathology.

2019-12-27 | GSE142633 | GEO

Spatial transcriptomics analysis of wild type, 5XFAD mice, 5XFAD mice treated with either vehicle or human neural stem cells (hNSC)

Project description:Spatial transcriptomics analysis was performed to detect differential gene expression in brain sections of of wild type, 5XFAD mice (model of Alzheimer's Disease), 5XFAD mice treated with either vehicle or human neural stem cells (hNSC)

2023-12-31 | GSE209583 | GEO

Sex-biased hippocampal pathology in the 5XFAD mouse model of Alzheimer's disease: A multi-omic analysis

Project description:Numerous neurological disorders, including Alzheimer's disease, display a sex-biased prevalence. To identify molecular correlates of this sex bias, we investigated sex-differences in molecular pathology in the hippocampus using the 5XFAD mouse model of Alzheimer's disease during early stages of disease progression (1, 2, and 4 months of age).

2019-02-13 | GSE97113 | GEO

Expression data from WT and TREM2 deficient microglia in a mouse model of Alzheimer's disease

Project description:We examined the role of TREM2 on microglia responses to amyloid-beta deposition in a mouse model of Alzheimer's disease Microglia were FACS-purified from 8.5 month old WT, Trem2-/-, 5XFAD, and Trem2-/- 5XFAD mice

2015-03-13 | E-GEOD-65067 | biostudies-arrayexpress

Next Generation Sequencing of 12 human platelet's miRNA for Alzheimer's disease study

Project description:We obtained miRNA expression information from 12 human platelet samples using the NGS method. The patient group was divided into "Normal Young", "Normal Old" and "Alzheimer's disease". Twenty miRNAs whose expression gradually changed in 3 groups were selected. Among them, miR150-3p and miR150-5p were highly correlated with each other and had a high correlation with the patient's age. In addition, the expression of miR-150-3p and miR-150-5p showed a miRNA-imbalance phenomenon in which the ratio was specifically changed in Alzheimer's disease.

2020-04-24 | GSE147714 | GEO

Transcriptomic effects of long-term pantethine treatment in the mouse Alzheimer's disease 5XFAD model

Project description:Pantethine, an anti-cholesterol drug, was shown to inhibit the Ab (amyloid beta) peptide-induced expression of IL-1b in primary culture astrocytes derived from either untreated Ab-treated and untreated 5XFAD or Ab-treated WT. These observations prompted us to investigate the effects of pantethine at the transcriptomic level in the mouse AD model.

2018-07-15 | E-MTAB-6772 | biostudies-arrayexpress

Next Generation Sequencing of 12 human platelet's miRNA for Alzheimer's disease study

Project description:Next Generation Sequencing of 12 human platelet's miRNA for Alzheimer's disease study

| PRJNA616243 | ENA

Effect of PD-1 immune checkpoint in Alzheimer's disease transgenic mice

Project description:We examined the brain's choroid plexus and myeloid cell populations isolated from the brain of 5XFAD Alzheimer's disease transgenic mice following PD-1 blockade

2017-01-01 | GSE75484 | GEO

Deep proteome profiling of hippocampus in 5xFAD mouse model

Project description:Alzheimer's disease (AD) is the most common neurodegenerative disease and characterized by the deposition of extracellular amyloid plaques and intracellular neurofibrillary tangles. Although extensive research was performed for Alzheimer's disease (AD) is the most common neurodegenerative disease and characterized by the deposition of extracellular amyloid plaques and intracellular neurofibrillary tangles. Although extensive research was performed for decades, the exact mechanisms and pathological causes of the disease still remain unknown. In order to perform comprehensive and integrative characterization of AD brain, assessment of global proteomic dynamics is required. We performed hippocampal proteome analysis to compare differentially expressed proteins in wild-type and 5XFAD model mice by label-free LC-MS. decades, the exact mechanisms and pathological causes of the disease still remain unknown. In order to perform comprehensive and integrative characterization of AD brain, assessment of global proteomic dynamics is required. We performed hippocampal proteome analysis to compare differentially expressed proteins in wild-type and 5XFAD model mice by label-free LC-MS.

2020-05-26 | PXD012238 | Pride

Alzheimer's model and vitamin D

Project description:Little is known about the global molecular changes leading to neurodegeneration and brain dysfunction in Alzheimer's disease (AD). To study the molecular cascades involved, we chose to study the transcriptomic profile of an early-onset AD model, the 5xFAD mice, at different time points (1 month, 4 months, 6 months and 9 months) of the disease. We are also interested in the effects of vitamin D supplementation in AD. Vitamin D receptor belongs to the family of nuclear receptors and vitamin D can act as a neurosteroid by regulating the expression of over a 1000 genes. We therefore decided to evaluate the effect of vitamin D supplementation in this AD mouse model at the transcriptomic level, after 5 months of supplementation (i.e. from 1 month to 6 months and from 4 months to 9 months).

2014-04-30 | E-MTAB-1937 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data